The North America U.S. In Vitro Diagnostics (IVD) Market was valued at USD 32,750 Million in 2025 and is expected to reach USD 58,430 Million by 2035, growing at a CAGR of 6.0% from 2024 to 2035. Driven by technological advancements, rising demand for rapid diagnostics, and personalized medicine, the IVD market is witnessing robust growth in the United States.
The economic impact of tariffs on "North America U.S. In Vitro Diagnostics (IVD) Market".
Market Growth Drivers
Advancements in Technological Innovation: Companies like Abbott and Roche Diagnostics are pioneering advanced molecular diagnostic platforms. Abbott's Alinity systems and Roche’s cobas® platforms integrate automation, high-throughput processing, and improved accuracy, driving the adoption of IVD solutions in clinical laboratories. The push for more efficient, multiplexed tests has allowed healthcare providers to detect multiple pathogens simultaneously, significantly improving patient outcomes and lab productivity.
Rising Prevalence of Chronic and Infectious Diseases: The increasing incidence of diseases such as diabetes, cancer, and COVID-19 is fueling demand for improved diagnostic tools. Companies like Thermo Fisher Scientific are expanding their portfolio of assays for both chronic and emerging infectious diseases. The growing requirement for early, accurate, and non-invasive testing in disease management is propelling market growth across health systems in the United States.
Market Trends
Expansion of Point-of-Care Testing (POCT): The U.S. IVD market is experiencing a strong shift towards decentralized testing with expanding Point-of-Care Testing solutions. Abbott’s ID NOW and Cepheid’s GeneXpert platforms are significantly reducing turnaround times for critical diagnostics, especially in emergency and outpatient settings. This movement is supported by growing demand for immediate results in infectious disease detection, cardiac markers, and diabetes monitoring.
Increased Investment in Personalized and Companion Diagnostics: With the rise of personalized medicine, companies like Qiagen and Illumina are developing next-generation sequencing-based diagnostics tailored to patient-specific genetic profiles. The integration of companion diagnostics with targeted therapies enables precise treatment regimens for oncology and rare genetic disorders, helping providers optimize patient care and fueling market expansion.
Market Opportunity
Growth in Home-Based Testing Solutions: Leading companies such as Siemens Healthineers are investing in user-friendly home diagnostic kits, providing opportunities for remote disease monitoring and management, which can improve healthcare accessibility and reduce the burden on clinical laboratories.
Digital Health Integration: Companies including Becton Dickinson are leveraging digital health technologies to enable seamless connection between IVD systems and electronic health records, enabling better data-driven decisions and streamlined clinical workflow for providers across the U.S.
North America U.S. IVD Market Revenue (USD Million), 2020-2035
The chart illustrates steady revenue growth for the U.S. IVD market from 2020 (USD 23,560 Million) to 2035 (USD 58,430 Million), reflecting increasing demand for advanced diagnostics, expanding test menus, and the impact of factors such as population aging and chronic disease prevalence. There is a noticeable spike in revenue during and right after the COVID-19 pandemic years (2020-2022), followed by sustained growth as routine and specialty testing volumes expand. The CAGR from 2024 to 2035 is approximately 6%, with notable gains from both laboratory and point-of-care segments.
North America U.S. IVD Market Share by Regions, 2025
The 2025 pie chart depicts the regional segmentation of the U.S. IVD market, with the South holding the lead due to a large population base and substantial healthcare infrastructure investments. The Midwest and West follow, with notable shares attributed to the presence of key life science clusters and research institutions. The Northeast holds a significant share given its concentration of academic medical centers and innovation hubs. Other regions collectively contribute the remaining share, underscoring the market’s nationwide reach and adoption of IVD technologies.
Recent Developments in the U.S. IVD Market
In April 2024, Abbott received FDA clearance for its Alinity m Respiratory Panel, enhancing its molecular diagnostics portfolio. This comprehensive panel delivers rapid, accurate detection of multiple respiratory pathogens, significantly improving clinical workflow and turnaround times in acute care settings. The launch aligns with providers’ priorities for scalable and adaptable testing following the COVID-19 pandemic.
In May 2024, Roche Diagnostics announced a strategic partnership with Salesforce to digitize laboratory data management and reporting across U.S. hospital networks. By integrating cloud-based analytics and AI-driven reporting, this collaboration is expected to drive process innovation and real-time data-driven decision-making in IVD testing for both labs and clinicians.
In June 2024, Thermo Fisher Scientific launched a new generation of liquid biopsy assays for oncology applications, utilizing proprietary next-generation sequencing technology with higher sensitivity and specificity for cancer detection. This release marks an important step in non-invasive cancer diagnostics and supports the increasing trend toward precision medicine and early intervention.
Press Releases